{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T02:45:40Z","timestamp":1792118740689,"version":"4.4.0"},"reference-count":162,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.blre.2025.101339","type":"journal-article","created":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T22:25:31Z","timestamp":1759011931000},"page":"101339","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Management of relapsed refractory multiple myeloma: Evidence-based guide to community oncologists"],"prefix":"10.1016","volume":"74","author":[{"given":"Ali","family":"Mushtaq","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asfand Yar","family":"Cheema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hossam M.","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yara","family":"Shatnawi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omer","family":"Ashruf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eman Nayaz","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Lytvynova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mishaal","family":"Munir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Anns","family":"Asif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maheen","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamza","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah M.","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tara","family":"Roy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aneela","family":"Majeed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahzad","family":"Raza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Mazzoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack","family":"Khouri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Valent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christy","family":"Samaras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joslyn","family":"Rudoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beth M.","family":"Faiman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikhaila","family":"Rice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Kissam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Basali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faiz","family":"Anwer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.blre.2025.101339_bb0005","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1200\/JCO.18.02096","article-title":"Treatment of multiple myeloma: ASCO and CCO joint clinical practice guideline","volume":"37","author":"Mikhael","year":"2019","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.blre.2025.101339_bb0010","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1002\/ajh.26379","article-title":"Chimeric antigen receptor T-cells, bispecific antibodies, and antibody-drug conjugates for multiple myeloma: an update","volume":"97","author":"Lakshman","year":"2022","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2025.101339_bb0015","first-page":"164","article-title":"The management of relapsed and refractory multiple myeloma","volume":"37","author":"Gahvari","year":"2023","journal-title":"Oncology (Williston Park)"},{"key":"10.1016\/j.blre.2025.101339_bb0020","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1182\/blood.2021011101","article-title":"Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, and MAIA","volume":"139","author":"Cavo","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101339_bb0025","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2025.101339_bb0030","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.blre.2025.101339_bb0035","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1182\/hematology.2020000110","article-title":"Bispecifics, trispecifics, and other novel immune treatments in myeloma","volume":"2020","author":"Lancman","year":"2020","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.blre.2025.101339_bb0040","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2025.101339_bb0045","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International myeloma working group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.blre.2025.101339_bb0050","doi-asserted-by":"crossref","first-page":"6192","DOI":"10.3390\/ijms25116192","article-title":"Current novel targeted therapeutic strategies in multiple myeloma","volume":"25","author":"Lin","year":"2024","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.blre.2025.101339_bb0055","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1038\/s41571-024-00913-y","article-title":"Just scratching the surface: novel treatment approaches for multiple myeloma targeting cell membrane proteins","volume":"21","author":"Neri","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.blre.2025.101339_bb0060","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1038\/s41375-020-0868-z","article-title":"Isatuximab plus pomalidomide and dexamethasone in relapsed\/refractory multiple myeloma patients with renal impairment: ICARIA-MM subgroup analysis","volume":"35","author":"Dimopoulos","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2025.101339_bb0065","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1182\/hematology.2022000346","article-title":"Fitness and frailty in myeloma","volume":"2022","author":"Pawlyn","year":"2022","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.blre.2025.101339_bb0070","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1056\/NEJMoa2505133","article-title":"Measurable residual disease\u2013guided therapy in newly diagnosed myeloma","volume":"393","author":"Perrot","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2025.101339_bb0075","doi-asserted-by":"crossref","first-page":"2938","DOI":"10.3390\/cancers16172938","article-title":"Comparative meta-analysis of triplet vs. quadruplet induction regimens in newly diagnosed, treatment na\u00efve, multiple myeloma","volume":"16","author":"Paul","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.blre.2025.101339_bb0080","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.3390\/cancers17121943","article-title":"Upfront anti-CD38 monoclonal antibody-based quadruplet therapy for multiple myeloma: a systematic review and meta-analysis of clinical trials","volume":"17","author":"Ntanasis-Stathopoulos","year":"2025","journal-title":"Cancers"},{"key":"10.1016\/j.blre.2025.101339_bb0085","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1002\/ajh.26640","article-title":"Impact of autologous hematopoietic cell transplantation on disease burden quantified by next-generation sequencing in multiple myeloma treated with quadruplet therapy","volume":"97","author":"Bal","year":"2022","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2025.101339_bb0090","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.6004\/jnccn.2023.7100","article-title":"Integrating immune therapies for the treatment of multiple myeloma","volume":"21","author":"Mikkilineni","year":"2023","journal-title":"J Natl Compr Cancer Netw JNCCN"},{"key":"10.1016\/j.blre.2025.101339_bb0095","doi-asserted-by":"crossref","first-page":"2766","DOI":"10.1200\/JCO-25-00760","article-title":"Long-term (\u22655-Year) remission and survival after treatment with ciltacabtagene autoleucel in CARTITUDE-1 patients with relapsed\/refractory multiple myeloma","volume":"43","author":"Jagannath","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2025.101339_bb0100","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/S1470-2045(14)70245-1","volume":"15","author":"Cook","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.blre.2025.101339_bb0105","doi-asserted-by":"crossref","first-page":"2438","DOI":"10.1002\/cncr.28104","article-title":"Autologous retransplantation for patients with recurrent multiple myeloma","volume":"119","author":"Sellner","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.blre.2025.101339_bb0110","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.1038\/s41409-021-01371-1","article-title":"Outcomes after delayed and second autologous stem cell transplant in patients with relapsed multiple myeloma","volume":"56","author":"Lemieux","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.blre.2025.101339_bb0115","doi-asserted-by":"crossref","first-page":"3329","DOI":"10.2169\/internalmedicine.9097-21","article-title":"Bortezomib-thalidomide-dexamethasone-cisplatin-doxorubicin-cyclophosphamide-etoposide as a salvage and bridging regimen before hematopoietic stem cell transplantation for relapsed or refractory multiple myeloma","volume":"61","author":"Togano","year":"2022","journal-title":"Intern Med Tokyo Jpn"},{"key":"10.1016\/j.blre.2025.101339_bb0120","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1182\/blood-2017-03-726703","article-title":"How I treat first relapse of myeloma","volume":"130","author":"Harousseau","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101339_bb0125","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1080\/19420862.2015.1007813","article-title":"Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma","volume":"7","author":"Overdijk","year":"2015","journal-title":"mAbs"},{"key":"10.1016\/j.blre.2025.101339_bb0130","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1038\/s41375-020-0711-6","article-title":"Daratumumab plus lenalidomide and dexamethasone in relapsed\/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study","volume":"34","author":"Bahlis","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2025.101339_bb0135","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1200\/JCO.21.02734","article-title":"Overall survival with daratumumab, bortezomib, and dexamethasone in previously treated multiple myeloma (CASTOR): a randomized, open-label, Phase III Trial","volume":"41","author":"Sonneveld","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2025.101339_bb0140","doi-asserted-by":"crossref","first-page":"3739","DOI":"10.1182\/bloodadvances.2023010026","article-title":"Final analysis of carfilzomib, dexamethasone, and daratumumab vs carfilzomib and dexamethasone in the CANDOR study","volume":"7","author":"Usmani","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2025.101339_bb0145","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1016\/S0140-6736(21)00592-4","article-title":"Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial","volume":"397","author":"Moreau","year":"2021","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.blre.2025.101339_bb0150","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1200\/JCO.2017.76.5032","article-title":"Improvement in overall survival with carfilzomib, lenalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma","volume":"36","author":"Siegel","year":"2018","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.blre.2025.101339_bb0155","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.clml.2022.01.011","article-title":"Treatment options for patients with heavily pretreated relapsed and refractory multiple myeloma","volume":"22","author":"Dimopoulos","year":"2022","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.blre.2025.101339_bb0160","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1056\/NEJMoa1516282","article-title":"Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"374","author":"Moreau","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2025.101339_bb0165","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.1182\/blood-2017-06-791228","article-title":"Ixazomib significantly prolongs progression-free survival in high-risk relapsed\/refractory myeloma patients","volume":"130","author":"Avet-Loiseau","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101339_bb0170","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1182\/blood-2015-05-643320","article-title":"Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma","volume":"126","author":"Shah","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101339_bb0175","doi-asserted-by":"crossref","first-page":"5703","DOI":"10.1182\/bloodadvances.2022008866","article-title":"Phase 1\/2 study of carfilzomib, pomalidomide, and dexamethasone with and without daratumumab in relapsed multiple myeloma","volume":"7","author":"Derman","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2025.101339_bb0180","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1080\/10428194.2024.2322030","article-title":"An open-label phase 2 study treating patients with first or second relapse of multiple myeloma with carfilzomib, pomalidomide, and dexamethasone (KPd): SELECT study","volume":"65","author":"Perrot","year":"2024","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.blre.2025.101339_bb0185","doi-asserted-by":"crossref","first-page":"2694","DOI":"10.3324\/haematol.2021.278399","article-title":"Carfilzomib or bortezomib in combination with cyclophosphamide and dexamethasone followed by carfilzomib maintenance for patients with multiple myeloma after one prior therapy: results from a multicenter, phase II, randomized, controlled trial (MUKfive)","volume":"106","author":"Yong","year":"2021","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2025.101339_bb0190","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/bjh.18185","article-title":"How I treat triple-class refractory multiple myeloma","volume":"198","author":"Costa","year":"2022","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2025.101339_bb0195","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/S1470-2045(21)00128-5","article-title":"Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial","volume":"22","author":"Dimopoulos","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.blre.2025.101339_bb0200","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S1470-2045(19)30152-4","article-title":"Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial","volume":"20","author":"Richardson","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.blre.2025.101339_bb0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2021.106576","article-title":"Isatuximab plus pomalidomide and dexamethasone in patients with relapsed\/refractory multiple myeloma according to prior lines of treatment and refractory status: ICARIA-MM subgroup analysis","volume":"104","author":"Bringhen","year":"2021","journal-title":"Leuk Res"},{"key":"10.1016\/j.blre.2025.101339_bb0210","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1016\/S0140-6736(19)32556-5","article-title":"Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study","volume":"394","author":"Attal","year":"2019","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.blre.2025.101339_bb0215","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/S1470-2045(22)00019-5","article-title":"Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study","volume":"23","author":"Richardson","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.blre.2025.101339_bb0220","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T cell therapy: current limitations and potential strategies","volume":"11","author":"Sterner","year":"2021","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.blre.2025.101339_bb0225","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s13045-016-0284-z","article-title":"Elotuzumab for the treatment of multiple myeloma","volume":"9","author":"Wang","year":"2016","journal-title":"J Hematol OncolJ Hematol Oncol"},{"key":"10.1016\/j.blre.2025.101339_bb0230","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.critrevonc.2013.04.003","article-title":"CS1, a SLAM family receptor involved in immune regulation, is a therapeutic target in multiple myeloma","volume":"88","author":"Veillette","year":"2013","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.blre.2025.101339_bb0235","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1505654","article-title":"Elotuzumab therapy for relapsed or refractory multiple myeloma","volume":"373","author":"Lonial","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2025.101339_bb0240","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1200\/JCO.21.02815","article-title":"Elotuzumab plus pomalidomide and dexamethasone for relapsed\/refractory multiple myeloma: final overall survival analysis from the randomized phase II ELOQUENT-3 Trial","volume":"41","author":"Dimopoulos","year":"2023","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.blre.2025.101339_bb0245","doi-asserted-by":"crossref","first-page":"78883","DOI":"10.18632\/oncotarget.12428","article-title":"Selinexor, a selective inhibitor of nuclear export (SINE) compound, acts through NF-\u03baB deactivation and combines with proteasome inhibitors to synergistically induce tumor cell death","volume":"7","author":"Kashyap","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.blre.2025.101339_bb0250","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1016\/S0140-6736(20)32292-3","article-title":"Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial","volume":"396","author":"Grosicki","year":"2020","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.blre.2025.101339_bb0255","doi-asserted-by":"crossref","first-page":"e286","DOI":"10.1016\/j.clml.2023.06.001","article-title":"Selinexor-based triplet regimens in patients with multiple myeloma previously treated with anti-CD38 monoclonal antibodies","volume":"23","author":"Schiller","year":"2023","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.blre.2025.101339_bb0260","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1002\/jha2.572","article-title":"Selinexor-based regimens in patients with multiple myeloma after prior anti-B-cell maturation antigen treatment","volume":"3","author":"Baljevic","year":"2022","journal-title":"EJHaem"},{"key":"10.1016\/j.blre.2025.101339_bb0265","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1352281","article-title":"Efficacy and safety of once weekly selinexor 40 mg versus 60 mg with pomalidomide and dexamethasone in relapsed and\/or refractory multiple myeloma","volume":"14","author":"White","year":"2024","journal-title":"Front Oncol"},{"key":"10.1016\/j.blre.2025.101339_bb0270","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1275329","article-title":"Impacting T-cell fitness in multiple myeloma: potential roles for selinexor and XPO1 inhibitors","volume":"14","author":"Binder","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.blre.2025.101339_bb0275","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1126\/science.abg1209","article-title":"Bispecific antibodies","volume":"372","author":"Brinkmann","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.blre.2025.101339_bb0280","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1038\/s41591-023-02589-w","article-title":"Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial","volume":"29","author":"Bahlis","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.blre.2025.101339_bb0285","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","article-title":"Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results","volume":"29","author":"Lesokhin","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.blre.2025.101339_bb0290","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1200\/JCO.24.01008","article-title":"Linvoseltamab for treatment of relapsed\/refractory multiple myeloma","volume":"42","author":"Bumma","year":"2024","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.blre.2025.101339_bb0295","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","article-title":"Talquetamab, a T-Cell-Redirecting GPRC5D bispecific antibody for multiple myeloma","volume":"387","author":"Chari","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2025.101339_bb0300","article-title":"Targeting GPRC5D with talquetamab: a new frontier in bispecific antibody therapy for relapsed\/refractory multiple myeloma","author":"Shaver","year":"2024","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.blre.2025.101339_bb0305","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1007\/s40265-023-01945-x","article-title":"Talquetamab: first approval","volume":"83","author":"Keam","year":"2023","journal-title":"Drugs"},{"key":"10.1016\/j.blre.2025.101339_bb0310","doi-asserted-by":"crossref","first-page":"3746","DOI":"10.1002\/cncr.34987","article-title":"Single-agent belantamab mafodotin in patients with relapsed\/refractory multiple myeloma: final analysis of the DREAMM-2 trial","volume":"129","author":"Nooka","year":"2023","journal-title":"Cancer"},{"key":"10.1016\/j.blre.2025.101339_bb0315","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJMoa2405090","article-title":"Belantamab mafodotin, bortezomib, and dexamethasone for multiple myeloma","volume":"391","author":"Hungria","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2025.101339_bb0320","doi-asserted-by":"crossref","first-page":"e801","DOI":"10.1016\/S2352-3026(23)00243-0","article-title":"Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, randomised study","volume":"10","author":"Dimopoulos","year":"2023","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.blre.2025.101339_bb0325","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1182\/blood.2024024582","article-title":"Ide-cel vs standard regimens in triple-class\u2013exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses","volume":"144","author":"Ailawadhi","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101339_bb0330","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa2303379","article-title":"Cilta-cel or standard care in lenalidomide-refractory multiple myeloma","volume":"389","author":"San-Miguel","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2025.101339_bb0335","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1158\/1078-0432.CCR-21-3803","article-title":"FDA approval summary: idecabtagene vicleucel for relapsed or refractory multiple myeloma","volume":"28","author":"Sharma","year":"2022","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"10.1016\/j.blre.2025.101339_bb0340","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1080\/03007995.2024.2391112","article-title":"Comparative efficacy of ciltacabtagene autoleucel versus idecabtagene vicleucel in the treatment of patients with relapsed or refractory multiple myeloma previously treated with 2-4 prior lines of therapy: a matching-adjusted indirect comparison","volume":"40","author":"Bar","year":"2024","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.blre.2025.101339_bb0345","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.jtct.2024.02.019","article-title":"Clinical outcomes and toxicity in older adults receiving chimeric antigen receptor T cell therapy","volume":"30","author":"Johnson","year":"2024","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.blre.2025.101339_bb0350","doi-asserted-by":"crossref","first-page":"4671","DOI":"10.3390\/cancers15184671","article-title":"Outcomes of chimeric antigen receptor (CAR) T-Cell therapy in patients with large B-Cell lymphoma (LBCL): a single-institution experience","volume":"15","author":"Trando","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.blre.2025.101339_bb0355","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s13045-022-01296-2","article-title":"Patient selection for CAR T or BiTE therapy in multiple myeloma: which treatment for each patient?","volume":"15","author":"Kegyes","year":"2022","journal-title":"J Hematol OncolJ Hematol Oncol"},{"key":"10.1016\/j.blre.2025.101339_bb0360","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2025029773","article-title":"Sequential targeting in multiple myeloma: talquetamab, a GPRC5D bispecific antibody, as a bridge to BCMA CAR-T cell therapy","author":"Dhakal","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101339_bb0365","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1182\/blood-2024-202017","article-title":"Talquetamab bridging: paving the way to B-Cell maturation antigen (BCMA) CAR-T Cell therapy in relapsed\/refractory multiple myeloma (RRMM)","volume":"144","author":"Dhakal","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101339_bb0370","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s41408-025-01225-9","article-title":"Risk factors for CAR T-cell manufacturing failure and patient outcomes in large B-cell lymphoma: a report from the UK National CAR T Panel","volume":"15","author":"Dulobdas","year":"2025","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.blre.2025.101339_bb0375","doi-asserted-by":"crossref","DOI":"10.3389\/frtra.2023.1238535","article-title":"Promises and challenges of a decentralized CAR T-cell manufacturing model","volume":"2","author":"Shah","year":"2023","journal-title":"Front Transplant"},{"key":"10.1016\/j.blre.2025.101339_bb0380","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.28877","article-title":"Geographic and racial disparities in access to chimeric antigen Receptor-T Cells and bispecific antibodies trials for multiple myeloma","volume":"5","author":"Alqazaqi","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.blre.2025.101339_bb0385","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-010064","article-title":"Comparison of CAR T-cell and bispecific antibody as third-line or later-line treatments for multiple myeloma: a meta-analysis","volume":"12","author":"Liang","year":"2024","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.blre.2025.101339_bb0390","doi-asserted-by":"crossref","first-page":"6330","DOI":"10.3390\/curroncol30070467","article-title":"Toxicity profile of chimeric antigen receptor T-Cell and bispecific antibody therapies in multiple myeloma: pathogenesis, prevention and management","volume":"30","author":"Markouli","year":"2023","journal-title":"Curr Oncol Tor Ont"},{"key":"10.1016\/j.blre.2025.101339_bb0395","doi-asserted-by":"crossref","first-page":"e255","DOI":"10.1016\/S1470-2045(23)00159-6","article-title":"Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network","volume":"24","author":"Ludwig","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.blre.2025.101339_bb0400","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1002\/ajh.26269","article-title":"Venetoclax for the treatment of multiple myeloma: outcomes outside of clinical trials","volume":"96","author":"Sidiqi","year":"2021","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2025.101339_bb0405","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2019.100643","article-title":"The evolving role of translocation t(11;14) in the biology, prognosis, and management of multiple myeloma","volume":"41","author":"Paner","year":"2020","journal-title":"Blood Rev"},{"key":"10.1016\/j.blre.2025.101339_bb0410","doi-asserted-by":"crossref","first-page":"533","DOI":"10.3389\/fonc.2018.00533","article-title":"Role and Regulation of Pro-survival BCL-2 proteins in multiple myeloma","volume":"8","author":"Slomp","year":"2018","journal-title":"Front Oncol"},{"key":"10.1016\/j.blre.2025.101339_bb0415","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1182\/blood-2017-06-788786","article-title":"Efficacy of venetoclax as targeted therapy for relapsed\/refractory t(11;14) multiple myeloma","volume":"130","author":"Kumar","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101339_bb0420","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.6004\/jnccn.2023.0061","article-title":"Multiple myeloma, version 2.2024, NCCN clinical practice guidelines in oncology","volume":"21","author":"Kumar","year":"2023","journal-title":"J Natl Compr Cancer Netw JNCCN"},{"key":"10.1016\/j.blre.2025.101339_bb0425","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1016\/S1470-2045(20)30525-8","article-title":"Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial","volume":"21","author":"Kumar","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.blre.2025.101339_bb0430","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1038\/s41467-021-21177-5","article-title":"Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma","volume":"12","author":"Samur","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.blre.2025.101339_bb0435","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1433774","article-title":"Mechanisms and salvage treatments in patients with multiple myeloma relapsed post-BCMA CAR-T cell therapy","volume":"15","author":"Fu","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.blre.2025.101339_bb0440","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2025.101256","article-title":"Mechanisms for resistance to BCMA-targeted immunotherapies in multiple myeloma","volume":"70","author":"Yue","year":"2025","journal-title":"Blood Rev"},{"key":"10.1016\/j.blre.2025.101339_bb0445","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1182\/blood.2022017848","article-title":"Interventions and outcomes of patients with multiple myeloma receiving salvage therapy after BCMA-directed CAR T therapy","volume":"141","author":"Van Oekelen","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101339_bb0450","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1182\/blood.2022015526","article-title":"Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents","volume":"141","author":"Cohen","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101339_bb0455","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood.2023023616","article-title":"Efficacy and safety of teclistamab in patients with relapsed\/refractory multiple myeloma after BCMA-targeting therapies","volume":"144","author":"Touzeau","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101339_bb0460","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.16_suppl.e20049","article-title":"Sequencing bispecific antibodies and CAR T cell therapy in multiple myeloma with prior exposure to BCMA-targeted therapies","volume":"41","author":"Patel","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2025.101339_bb0465","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1182\/bloodadvances.2023012066","article-title":"Salvage therapies including retreatment with BCMA-directed approaches after BCMA CAR-T relapses for multiple myeloma","volume":"8","author":"Reyes","year":"2024","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2025.101339_bb0470","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1056\/NEJMoa2209900","article-title":"GPRC5D-Targeted CAR T cells for myeloma","volume":"387","author":"Mailankody","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2025.101339_bb0475","doi-asserted-by":"crossref","first-page":"3371","DOI":"10.1038\/s41467-024-47801-8","article-title":"Bispecific CAR T cell therapy targeting BCMA and CD19 in relapsed\/refractory multiple myeloma: a phase I\/II trial","volume":"15","author":"Shi","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.blre.2025.101339_bb0480","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.critrevonc.2019.02.011","article-title":"Special considerations for the treatment of multiple myeloma according to advanced age, comorbidities, frailty and organ dysfunction","volume":"137","author":"Fraz","year":"2019","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.blre.2025.101339_bb0485","doi-asserted-by":"crossref","first-page":"21","DOI":"10.4065\/78.1.21","article-title":"Review of 1027 patients with newly diagnosed multiple myeloma","volume":"78","author":"Kyle","year":"2003","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.blre.2025.101339_bb0490","doi-asserted-by":"crossref","first-page":"225","DOI":"10.4065\/mcp.2009.0426","article-title":"Patterns of multiple myeloma during the past 5 decades: stable incidence rates for all age groups in the population but rapidly changing age distribution in the clinic","volume":"85","author":"Turesson","year":"2010","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.blre.2025.101339_bb0495","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1080\/14656566.2019.1577822","article-title":"The pharmacologic management of multiple myeloma in older adults","volume":"20","author":"Dempsey","year":"2019","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.blre.2025.101339_bb0500","doi-asserted-by":"crossref","first-page":"151","DOI":"10.3390\/hematolrep15010015","article-title":"Frail multiple myeloma patients deserve more than just a score","volume":"15","author":"Miller","year":"2023","journal-title":"Hematol Rep"},{"key":"10.1016\/j.blre.2025.101339_bb0505","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1182\/blood-2014-12-615187","article-title":"Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an international myeloma working group report","volume":"125","author":"Palumbo","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101339_bb0510","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s12185-020-02988-6","article-title":"Clinical impact of frailty on treatment outcomes of elderly patients with relapsed and\/or refractory multiple myeloma treated with lenalidomide plus dexamethasone","volume":"113","author":"Lee","year":"2021","journal-title":"Int J Hematol"},{"key":"10.1016\/j.blre.2025.101339_bb0515","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.clml.2016.11.009","article-title":"Incidence and risk of cardiac events in patients with previously treated multiple myeloma versus matched patients without multiple myeloma: an observational, retrospective, cohort study","volume":"17","author":"Kistler","year":"2017","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.blre.2025.101339_bb0520","doi-asserted-by":"crossref","first-page":"610","DOI":"10.3390\/cancers14030610","article-title":"High output heart failure in multiple myeloma: pathogenetic considerations","volume":"14","author":"Carlisi","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.blre.2025.101339_bb0525","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s00280-016-3219-z","article-title":"Pharmacokinetics of lenalidomide during high cut-off dialysis in a patient with multiple myeloma and renal failure","volume":"79","author":"Dao","year":"2017","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.blre.2025.101339_bb0530","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1007\/s00277-020-04023-4","article-title":"The clinical management of lenalidomide-based therapy in patients with newly diagnosed multiple myeloma","volume":"99","author":"Merz","year":"2020","journal-title":"Ann Hematol"},{"key":"10.1016\/j.blre.2025.101339_bb0535","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1182\/blood-2008-04-149385","article-title":"Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature","volume":"112","author":"Argyriou","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101339_bb0540","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1111\/ejh.13643","article-title":"Dose intensity and treatment duration of bortezomib in transplant-ineligible newly diagnosed multiple myeloma","volume":"107","author":"Ibarra","year":"2021","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.blre.2025.101339_bb0545","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1159\/000503095","article-title":"Performance status assessment by using ECOG (eastern cooperative oncology group) score for cancer patients by oncology healthcare professionals","volume":"12","author":"Azam","year":"2019","journal-title":"Case Rep Oncol"},{"key":"10.1016\/j.blre.2025.101339_bb0550","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/1472-6947-13-72","article-title":"Appraisal of the Karnofsky performance status and proposal of a simple algorithmic system for its evaluation","volume":"13","author":"P\u00e9us","year":"2013","journal-title":"BMC Med Inform Decis Mak"},{"key":"10.1016\/j.blre.2025.101339_bb0555","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1111\/ejh.13426","article-title":"Impact of performance status on overall survival in patients with relapsed and\/or refractory multiple myeloma: Real-life outcomes of daratumumab treatment","volume":"105","author":"Afram","year":"2020","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.blre.2025.101339_bb0560","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1002\/cncr.25775","article-title":"Chromosomal aberrations +1q21 and del(17p13) predict survival in patients with recurrent multiple myeloma treated with lenalidomide and dexamethasone","volume":"117","author":"Klein","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.blre.2025.101339_bb0565","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1002\/ajh.26590","article-title":"Multiple myeloma: 2022 update on diagnosis, risk stratification, and management","volume":"97","author":"Rajkumar","year":"2022","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2025.101339_bb0570","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.934008","article-title":"Exploring the current molecular landscape and management of multiple myeloma patients with the t(11;14) translocation","volume":"12","author":"Diamantidis","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.blre.2025.101339_bb0575","doi-asserted-by":"crossref","first-page":"5829","DOI":"10.3390\/cancers15245829","article-title":"The role of t(11;14) in Tailoring treatment decisions in multiple myeloma","volume":"15","author":"Kleber","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.blre.2025.101339_bb0580","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1200\/JCO.2013.48.7934","article-title":"International myeloma working group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation","volume":"32","author":"Palumbo","year":"2014","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.blre.2025.101339_bb0585","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41375-019-0660-0","article-title":"Extramedullary multiple myeloma","volume":"34","author":"Bhutani","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2025.101339_bb0590","doi-asserted-by":"crossref","first-page":"264","DOI":"10.7555\/JBR.31.20140090","article-title":"Clinical features of multiple myeloma patients with isolated extramedullary relapse","volume":"32","author":"Qu","year":"2018","journal-title":"J Biomed Res"},{"key":"10.1016\/j.blre.2025.101339_bb0595","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1056\/NEJMoa2406536","article-title":"Talquetamab plus teclistamab in relapsed or refractory multiple myeloma","volume":"392","author":"Cohen","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2025.101339_bb0600","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/s41408-022-00695-5","article-title":"Gaps and opportunities in the treatment of relapsed-refractory multiple myeloma: consensus recommendations of the NCI multiple myeloma steering committee","volume":"12","author":"Kumar","year":"2022","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.blre.2025.101339_bb0605","doi-asserted-by":"crossref","first-page":"4320","DOI":"10.3390\/cancers13174320","article-title":"Choosing the right therapy for patients with relapsed\/refractory multiple myeloma (RRMM) in consideration of patient-, disease- and treatment-related factors","volume":"13","author":"Gengenbach","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.blre.2025.101339_bb0610","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/s41408-021-00432-4","article-title":"Management of patients with multiple myeloma beyond the clinical-trial setting: understanding the balance between efficacy, safety and tolerability, and quality of life","volume":"11","author":"Terpos","year":"2021","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.blre.2025.101339_bb0615","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1200\/EDBK_175171","article-title":"Myeloma in elderly patients: when less is more and more is more","volume":"37","author":"Rosko","year":"2017","journal-title":"Am Soc Clin Oncol Educ Book Am Soc Clin Oncol Annu Meet"},{"key":"10.1016\/j.blre.2025.101339_bb0620","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1182\/blood.2021012854","article-title":"Requirements for operational cure in multiple myeloma","volume":"138","author":"Mohty","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101339_bb0625","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.1200\/JCO.23.00934","article-title":"Minimal residual disease status in multiple myeloma 1 year after autologous hematopoietic cell transplantation and lenalidomide maintenance are associated with long-term overall survival","volume":"42","author":"Pasquini","year":"2024","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.blre.2025.101339_bb0630","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1182\/blood.2024024371","article-title":"EVIDENCE meta-analysis: evaluating minimal residual disease as an intermediate clinical end point for multiple myeloma","volume":"144","author":"Landgren","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101339_bb0635","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1200\/JCO.21.02228","article-title":"Minimal residual disease after autologous stem-cell transplant for patients with myeloma: prognostic significance and the impact of lenalidomide maintenance and molecular risk","volume":"40","author":"de Tute","year":"2022","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.blre.2025.101339_bb0640","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1007\/s11764-023-01332-1","article-title":"The impact of current therapeutic options on the health-related quality of life of patients with relapse\/refractory multiple myeloma: a systematic review of clinical studies","volume":"18","author":"Ojo","year":"2024","journal-title":"J Cancer Surviv Res Pract"},{"key":"10.1016\/j.blre.2025.101339_bb0645","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/j.jtct.2024.06.012","article-title":"Timing of toxicities and non-relapse mortality following CAR T therapy in myeloma","volume":"30","author":"Wesson","year":"2024","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.blre.2025.101339_bb0650","doi-asserted-by":"crossref","first-page":"17763","DOI":"10.1038\/s41598-025-02720-6","article-title":"Quality of life and symptom burden among hematologic malignancy patients undergoing CAR-T therapy: a cross-sectional study","volume":"15","author":"Dai","year":"2025","journal-title":"Sci Rep"},{"key":"10.1016\/j.blre.2025.101339_bb0655","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1158\/2159-8290.CD-21-1683","article-title":"Next-generation CAR T-cell therapies","volume":"12","author":"Young","year":"2022","journal-title":"Cancer Discov"},{"key":"10.1016\/j.blre.2025.101339_bb0660","doi-asserted-by":"crossref","first-page":"e107","DOI":"10.1016\/S2352-3026(22)00372-6","article-title":"GPRC5D CAR T cells (OriCAR-017) in patients with relapsed or refractory multiple myeloma (POLARIS): a first-in-human, single-centre, single-arm, phase 1 trial","volume":"10","author":"Zhang","year":"2023","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.blre.2025.101339_bb0665","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2022.100929","article-title":"Current state and next-generation CAR-T cells in multiple myeloma","volume":"54","author":"Manier","year":"2022","journal-title":"Blood Rev"},{"key":"10.1016\/j.blre.2025.101339_bb0670","doi-asserted-by":"crossref","first-page":"e521","DOI":"10.1016\/S2352-3026(19)30115-2","article-title":"A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial","volume":"6","author":"Yan","year":"2019","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.blre.2025.101339_bb0675","first-page":"2","article-title":"High efficacy and safety of CD38 and BCMA bispecific CAR-T in relapsed or refractory multiple myeloma","volume":"41","author":"Tang","year":"2022","journal-title":"J Exp Clin Cancer Res CR"},{"key":"10.1016\/j.blre.2025.101339_bb0680","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1186\/s13045-021-01170-7","article-title":"A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma","volume":"14","author":"Mei","year":"2021","journal-title":"J Hematol OncolJ Hematol Oncol"},{"key":"10.1016\/j.blre.2025.101339_bb0685","doi-asserted-by":"crossref","first-page":"e751","DOI":"10.1016\/S2352-3026(24)00176-5","article-title":"Anti-BCMA\/GPRC5D bispecific CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, single-centre, phase 1 trial","volume":"11","author":"Zhou","year":"2024","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.blre.2025.101339_bb0690","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1182\/bloodadvances.2022007210","article-title":"Phase 1 study of CART-ddBCMA for the treatment of subjects with relapsed and refractory multiple myeloma","volume":"7","author":"Frigault","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2025.101339_bb0695","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1182\/blood-2024-198499","article-title":"Phase 2 registrational study of anitocabtagene autoleucel for the treatment of patients with relapsed and\/or refractory multiple myeloma: preliminary results from the IMMagine-1 trial","volume":"144","author":"Freeman","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101339_bb0700","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1002\/ijc.34635","article-title":"Mechanisms and strategies for safe chimeric antigen receptor T-cell activity control","volume":"153","author":"Stock","year":"2023","journal-title":"Int J Cancer"},{"key":"10.1016\/j.blre.2025.101339_bb0705","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1038\/s41591-019-0421-7","article-title":"A safe and potent anti-CD19 CAR T cell therapy","volume":"25","author":"Ying","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.blre.2025.101339_bb0710","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1038\/s41591-022-02182-7","article-title":"Allogeneic BCMA-targeting CAR T cells in relapsed\/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results","volume":"29","author":"Mailankody","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.blre.2025.101339_bb0715","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1084\/jem.20031030","article-title":"Vigorous premalignancy-specific effector T cell response in the bone marrow of patients with monoclonal gammopathy","volume":"198","author":"Dhodapkar","year":"2003","journal-title":"J Exp Med"},{"key":"10.1016\/j.blre.2025.101339_bb0720","doi-asserted-by":"crossref","first-page":"146","DOI":"10.3390\/cells13020146","article-title":"Allogeneic CAR-T therapy technologies: has the promise been met?","volume":"13","author":"Lonez","year":"2024","journal-title":"Cells"},{"key":"10.1016\/j.blre.2025.101339_bb0725","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1182\/blood-2023-174841","article-title":"Updated results of a phase I open-label single-arm study of dual targeting BCMA and CD19 Fastcar-T Cells (GC012F) as first-line therapy for transplant-eligible newly diagnosed high-risk multiple myeloma","volume":"142","author":"Du","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101339_bb0730","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS8064","article-title":"CAMMA 2: A phase I\/II trial evaluating the efficacy and safety of cevostamab in patients with relapsed\/refractory multiple myeloma (RRMM) who have triple-class refractory disease and have received a prior anti-B-cell maturation antigen (BCMA) agent","volume":"41","author":"Kumar","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2025.101339_bb0735","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1158\/2643-3230.BCD-24-0118","article-title":"Bispecific antibodies as bridging to BCMA CAR-T cell therapy for relapsed\/refractory multiple myeloma","volume":"6","author":"Fandrei","year":"2025","journal-title":"Blood Cancer Discov"},{"key":"10.1016\/j.blre.2025.101339_bb0740","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/s41375-020-0834-9","article-title":"Phase 1 study of the anti-BCMA antibody-drug conjugate AMG 224 in patients with relapsed\/refractory multiple myeloma","volume":"35","author":"Lee","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2025.101339_bb0745","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1182\/blood-2020-141219","article-title":"TAK-573, an Anti-CD38\/Attenuated Ifn\u03b1 fusion protein, has clinical activity and modulates the Ifn\u03b1 receptor (IFNAR) pathway in patients with relapsed\/refractory multiple myeloma","volume":"136","author":"Vogl","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101339_bb0750","doi-asserted-by":"crossref","first-page":"4640","DOI":"10.1172\/JCI85856","article-title":"Antibody-drug conjugate targeting CD46 eliminates multiple myeloma cells","volume":"126","author":"Sherbenou","year":"2016","journal-title":"J Clin Invest"},{"key":"10.1016\/j.blre.2025.101339_bb0755","article-title":"Targeted interferon therapy with modakafusp alfa for relapsed or refractory multiple myeloma","author":"Vogl","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101339_bb0760","doi-asserted-by":"crossref","first-page":"4686","DOI":"10.1182\/blood-2023-187748","article-title":"Mezigdomide treatment in relapsed-refractory myeloma patients shifts bone marrow NK and T Cell populations from exhaustion to activation","volume":"142","author":"Chen","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101339_bb0765","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1056\/NEJMoa2303194","article-title":"Mezigdomide plus dexamethasone in relapsed and refractory multiple myeloma","volume":"389","author":"Richardson","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2025.101339_bb0770","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.3390\/cancers16061166","article-title":"Mezigdomide-A novel cereblon E3 ligase modulator under investigation in relapsed\/refractory multiple myeloma","volume":"16","author":"Hartley-Brown","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.blre.2025.101339_bb0775","doi-asserted-by":"crossref","first-page":"e822","DOI":"10.1016\/S2352-3026(22)00290-3","article-title":"Iberdomide plus dexamethasone in heavily pretreated late-line relapsed or refractory multiple myeloma (CC-220-MM-001): a multicentre, multicohort, open-label, phase 1\/2 trial","volume":"9","author":"Lonial","year":"2022","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.blre.2025.101339_bb0780","doi-asserted-by":"crossref","first-page":"767","DOI":"10.3389\/fonc.2019.00767","article-title":"Anti-CD19 chimeric antigen receptor T cells in combination with nivolumab are safe and effective against relapsed\/refractory B-Cell non-hodgkin lymphoma","volume":"9","author":"Cao","year":"2019","journal-title":"Front Oncol"},{"key":"10.1016\/j.blre.2025.101339_bb0785","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.832645","article-title":"Armored BCMA CAR T cells eliminate multiple myeloma and are resistant to the suppressive effects of TGF-\u03b2","volume":"13","author":"Alabanza","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.blre.2025.101339_bb0790","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1389971","article-title":"The synergistic immunotherapeutic impact of engineered CAR-T cells with PD-1 blockade in lymphomas and solid tumors: a systematic review","volume":"15","author":"Satapathy","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.blre.2025.101339_bb0795","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s00262-021-02959-8","article-title":"Lenalidomide enhances the efficacy of anti-BCMA CAR-T treatment in relapsed\/refractory multiple myeloma: a case report and revies of the literature","volume":"71","author":"Zhao","year":"2022","journal-title":"Cancer Immunol Immunother CII"},{"key":"10.1016\/j.blre.2025.101339_bb0800","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1158\/1535-7163.MCT-18-1146","article-title":"Anti-B-cell maturation antigen chimeric antigen receptor t cell function against multiple myeloma is enhanced in the presence of lenalidomide","volume":"18","author":"Works","year":"2019","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.blre.2025.101339_bb0805","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1158\/1078-0432.CCR-17-0344","article-title":"Lenalidomide enhances the function of CS1 chimeric antigen receptor-redirected T Cells against multiple myeloma","volume":"24","author":"Wang","year":"2018","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"10.1016\/j.blre.2025.101339_bb0810","doi-asserted-by":"crossref","DOI":"10.1200\/EDBK_159009","article-title":"Updated diagnostic criteria and staging system for multiple myeloma","author":"Rajkumar","year":"2016","journal-title":"Am Soc Clin Oncol Educ Book"}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X25000840?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X25000840?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T17:37:26Z","timestamp":1766079446000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X25000840"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":162,"alternative-id":["S0268960X25000840"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2025.101339","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of relapsed refractory multiple myeloma: Evidence-based guide to community oncologists","name":"articletitle","label":"Article Title"},{"value":"Blood Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.blre.2025.101339","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"101339"}}